The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Inclusion Criteria:

- Diagnosed with type 2 diabetes for at least 180 days prior to screening and treated
with stable basal insulin analogue dose of minimum 20 U/day with or without stable
metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening
(defined as insulin adjustments less than 10% during the past 8 weeks as assessed by
the investigator)

- HbA1c (glycosylated haemoglobin A1c) 7.0-10.0% (both inclusive)

- Body mass index (BMI) 20-45 kg/m^2 (both inclusive)

Exclusion Criteria:

- Female of child-bearing potential who is pregnant, breast-feeding or intending to
become pregnant

- Recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness

- Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria
in a period of 12 weeks prior to screening

- Impaired liver or renal function

- Uncontrolled treated or untreated hypertension (systolic blood pressure (SBP) equal
to or above 180 mmHg and/or diastolic blood pressure (DBP) equal to or above 100
mmHg)

- Any clinically significant disorder, except for conditions associated with type 2
diabetes history which in the investigator's opinion could interfere with results of
the trial

- Known or suspected abuse of alcohol or narcotics